Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Merck & Co., Inc. — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $29.24, while Merck & Co., Inc. trades at $124.76 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and Merck & Co., Inc. is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| KARS | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $129.52 |
52-Week Low | $23.61 | $77.60 |
Market Cap | — | $307.25B |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $29.15, down 0.98% with a bearish technical signal from moving averages and oscillators showing mixed signals. The stock faces headwinds from sector rotation away from traditional automakers toward efficient vehicles, as highlighted by recent news. Financial ratios are unavailable, limiting fundamental clarity, but the electric vehicle ETF context suggests exposure to evolving industry dynamics.
Outlook remains cautious due to technical weakness and sector pressures, though potential exists if EV adoption accelerates. Risks include competitive threats from Chinese automakers and regulatory uncertainty. Investors should await clearer financial data to assess valuation and growth prospects amid shifting market sentiment.
Merck (MRK) trades at $127.5, down slightly (-0.14%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, supported by earnings momentum, strategic acquisitions, and strong analyst buy ratings (67.57%). Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the pharmaceutical sector. The stock offers a dividend yield with a recent $0.85 per share payment, appealing for income-focused investors amid steady revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
